Will multiple myeloma treatment meet a new paradigm?

As a number of products emerges – DDP-4 inhibitors, SGLT-2 inhibitors, basal insulin and GLP-1 agonists –, ‘diabetes treatment’ has met a new treatment paradigm. Emergence of various treatments has allowed patients to have personalized treatments beyond existing treatments.

Yet, another treatment paradigm is getting ready for a change. That is the ‘multiple myeloma’ treatment market. Although ...